A new CT-based online calculator predicts survival benefits from adjuvant transarterial chemoembolization after surgical resection in hepatocellular carcinoma patients.

• 35.4% of patients evaluated may benefit from pa-tace, increasing 5-year overall survival probability by 19.4% and adding 22.5 months of restricted mean survival time.
• The tool outperforms traditional staging systems with a c-index of 0.694 and an integrated Brier score ≤ 0.176.

Surgeons can use this online resource to tailor postoperative protocols and address high-risk patients effectively.